Instituut voor Neuropathische Pijn
English articles Research & Development AL-309: Efficacy in animal models of neuropathy and neuropathic pain
| AL-309: Efficacy in animal models of neuropathy and neuropathic pain |
AL-309: Efficacy in animal models of neuropathy and neuropathic pain. According to a press release of the company, and we quote:
From a Press release of Allon Therapeutics on AL-309Preclinical data AL-309Allon Therapeutics Inc. announced on feb 23, 2010 preclinical data demonstrating the potential of AL-309, the Company's early-stage drug candidate. AL-309 is being investigated as a treatment for peripheral neuropathy, a debilitating and painful disorder of the peripheral nervous system afflicting millions of people for which there is no effective treatment. Bruce Morimoto, Ph.D., Allon's vice president of drug development, said the preclinical data has shown AL-309 to be effective at reducing nerve damage and pain in animal models for peripheral neuropathy caused by diabetes and cancer chemotherapy, two of the most common causes of the disease. Dr. Morimoto presented the data at the AsiaTIDES Oligonucleotide and Peptide Technology and Product Development Conference in Tokyo, Japan. AsiaTIDES focuses on technology and product development, manufacturing and partnering in the fields of oligonucleotide and peptide-based therapeutics and diagnostics. AL-309 anagesic action and neuroprotection"Our preclinical studies have shown that AL-309 not only reduced the pain symptoms associated with neuropathy, but also decreased nerve damage," said Morimoto. "Furthermore, the characteristics of AL-309 allow it to be developed for multiple routes of administration based on bioavailability studies using oral, intranasal, or subcutaneous application." "This demonstrated bioavailability for the three dosing routes provides flexibility for development and allows us to choose the most commercially attractive one. The commercial potential for AL-309 is underscored by the fact that drug sales in the U.S. and Europe amount to approximately $4 billion a year to treat neuropathic pain, yet these approved drugs are only moderately effective and have virtually no impact on the nerve damage that causes the pain," said Morimoto. Allon's neuroprotective platformsAllon's neuroprotetive technology platforms are based on two naturally occurring proteins produced by the brain in response to a range of insults. The platforms are activity-dependent neuroprotective protein (ADNP) and activity-dependent neurotrophic factor (ADNF). Because the two platforms are based on different proteins, the drugs from each are different molecules with different therapeutic mechanisms and distinct commercial opportunities. Clinical-stage drugs based on davunetide are derived from ADNP, while preclinical stage drug AL-309 is derived from ADNF. Davunetide is focused on Alzheimer's disease, cognitive impairment in schizophrenia, and frontotemporal dementia. ADNF drug candidate AL-309 is being developed for the treatment of peripheral neuropathies and is administered orally, intranasally or subcutaneously. Sourde: http://www.marketwatch.com/story/allon-presents-peripheral-neuropathy-preclinical-efficacy-data-for-al-309-2010-02-23-93210?reflink=MW_news_stmp |